So long as your health records show "obesity," you can exchange the weight you lose for beef, beef bones, or oxtail. This is ...

Weight loss jabs are being sold casually in pubs and fish and chip shops across London, according to a new report. Papers ...

The drug behind Ozempic has been found to restore joint cartilage in osteoarthritis, through a mechanism that works independently of weight loss.

Over the past two years, Eli Lilly (NYSE: LLY) has established itself as the leader in the weight loss market. That's thanks ...

Eli Lilly said the US drugmaker plans to invest USD3 billion in China over the coming decade to expand supply-chain ...

A $3 billion China investment targets localized oral solid-dose manufacturing and supply-chain redundancy to support ...

Pfizer Inc. (NYSE:PFE) is included among the 14 Low PE High Dividend Stocks to Buy Right Now. On March 6, Reuters reported that China has approved Pfizer Inc. (NYSE:PFE)’s GLP-1 treatment Xianweiying ...

Orforglipron, Eli Lilly’s oral obesity drug, is under FDA review with a decision expected in April. The pharma has also filed for marketing authorization for the pill in China.

The investment in China follows similar outlays by the drugmaker in other regions as it prepares for high orforglipron demand.

Eli Lilly (LLY) files a China marketing application for the oral GLP-1 weight loss drug orforglipron and pledges a $3B ...

Eli Lilly & Co will invest $3 billion in China over the next decade to expand local production, with a focus on weight loss as the US drugmaker looks to cement its dominance in the booming obesity ...

Eli Lilly plans to invest $3 billion in China over the next decade, which ​will help build production capacity for its experimental ‌type-2 diabetes and obesity treatment orforglipron, the U.S.